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Comparison of the Antibiotic Activities of Daptomycin, Vancomycin,
and the Investigational Fluoroquinolone Delafloxacin against Biofilms
from Staphylococcus aureus Clinical Isolates
Wafi Siala,a Marie-Paule Mingeot-Leclercq,a Paul M. Tulkens,a Marie Hallin,b* Olivier Denis,b Françoise Van Bambekea
Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgiuma; Laboratoire de Microbiologie et Centre de
Référence Belge des Staphylocoques, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgiumb
Biofilm-related infections remain a scourge. In an in vitromodel of biofilms using Staphylococcus aureus reference strains, dela-
floxacin and daptomycin were found to be the most active among the antibiotics from 8 different pharmacological classes (J.
Bauer, W. Siala, P. M. Tulkens, and F. Van Bambeke, Antimicrob. Agents Chemother. 57:2726–2737, 2013, doi:10.1128/
AAC.00181-13). In this study, we compared delafloxacin to daptomycin and vancomycin using biofilms produced by 7 clinical
strains (S. aureus epidemic clones CC5 and CC8) in order to rationalize the differences observed between the antibiotics and
strains. The effects of the antibiotics on bacterial viability (resazurin reduction assay) and biomass (crystal violet staining) were
measured and correlated with the proportion of polysaccharides in the matrix, the local microenvironmental pH (micro-pH),
and the antibiotic penetration in the biofilm. At clinically meaningful concentrations, delafloxacin, daptomycin, and vancomy-
cin caused a>25% reduction in viability against the biofilms formed by 5, 4, and 3 strains, respectively. The antibiotic penetra-
tion within the biofilms ranged from 0.6 to 52% for delafloxacin, 0.2 to 10% for daptomycin, and 0.2 to 1% for vancomycin; for
delafloxacin, this was inversely related to the polysaccharide proportion in the matrix. Six biofilms were acidic, explaining the
high potency of delafloxacin (lower MICs at acidic pH). Norspermidine and norspermine (disassembling the biofilmmatrix)
drastically increased delafloxacin potency and efficacy (50% reduction in viability for 6 biofilms at clinically meaningful concen-
trations) in direct correlation with its increased penetration within the biofilm, while they only modestly improved daptomycin
efficacy (50% reduction in viability for 2 biofilms) and penetration, and they showedmarginal effects with vancomycin. Dela-
floxacin potency and efficacy against biofilms are benefited by its penetration into the matrix and the local acidic micro-pH.
Biofilms consist of communities of bacteria encased in amatrixmade of polymeric substances, including DNA, proteins,
polysaccharides, and teichoic acids in Gram-positive bacteria.
About 80%of human bacterial infections are associatedwith these
structures that can develop on the surface of tissues or foreign
bodies (1). Staphylococcus aureus is one of the pathogens associ-
ated most frequently with these biofilm-related infections, and
more specifically those presenting a persistent character, like os-
teomyelitis, rhinosinusitis, otitis media, endocarditis, or orthope-
dic implant infections (2, 3).
Studies performed in vitro and in animal models have shown
that antibiotics are less active against bacteria growing in biofilms
than against their planktonic counterparts (4–9). This apparent
resistance has been attributed to a conjunction of factors related to
the metabolic state of bacteria (a slow growth rate, emergence of
small colony variants, and the presence of a significant population
of persisters [cells in a dormant state]), the heterogeneity of the
environment (gradients of pH, nutrients, or oxygen within the
biofilm), or the obstacle to antibiotic access imposed by thematrix
(binding, inactivation, or poor diffusion). Yet, direct experimen-
tal evidence of a cause-and-effect relationship between these fac-
tors and the lack of efficacy of antibiotics is not always well docu-
mented (1).
We recently developed an in vitro pharmacodynamic model
allowing for a comparison of antibiotic relative potencies and
maximal efficacies against biofilms of S. aureus which used quan-
titative and qualitative approaches in parallel (10). This model
showed that among the antibiotics from 8 pharmacological
classes, the investigational fluoroquinolone delafloxacin (11, 12)
and daptomycin performed better than all others when tested
against biofilms formed by both methicillin-susceptible S. aureus
(MSSA) and methicillin-resistant S. aureus (MRSA) reference
strains (ATCC 25923 and ATCC 33591). In the present study, we
extended the analysis to biofilms produced by 7 clinical isolates
belonging to multilocus sequence typing clonal complexes (CC)
CC5 and CC8, two of the most pandemic human lineages that
have acquiredmobile genetic elements carrying drug resistance or
virulence genes, making then well adapted for colonization,
pathogenicity, and a poor response to antibiotic treatment (13).
Delafloxacin was compared to daptomycin and vancomycin as
typical examples of highly and poorly active antibiotics, respec-
tively, when tested in biofilms formed from the reference strains
(10). We found that the biofilms produced from the clinical
strains tested were generally much more refractory to antibiotics
than those produced by reference strains, withmarked differences
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among the strains, but delafloxacin and daptomycin were more
active than vancomycin. For delafloxacin, activity was dependent
on biofilm pH and on the antibiotic penetration within the bio-
film, which was itself related to the proportion of carbohydrates
present in the matrix. Our data therefore suggest that examining
biofilm properties may help predict antibiotic activity. We also
show that destructuring thematrix bymeans of polycationic com-
pounds, such as norspermine or norspermidine, greatly increases
delafloxacin activity by improving its diffusion, underlining the
interest in developing adjunctive therapies for the treatment of
biofilm-related infections.
MATERIALS AND METHODS
Materials. Delafloxacin (95.7% potency) was procured from Melinta
Therapeutics (New Haven, CT), and daptomycin (100% potency) was
fromNovartis Pharma AG (Basel, Switzerland). Vancomycin was used as
a powder for injection (chlorhydrate form, without excipients) approved
for human use in Belgium and in compliance with the provisions of the
European Pharmacopoeia (Vancomycine Mylan; Mylan, Inc., Canons-
burg, PA). Norspermidine and norspermine were from Sigma-Aldrich
(St. Louis,MO). Fluorescent products (including Bodipy-FL-labeled van-
comycin) were obtained from Molecular Probes (Eugene, OR), except
Bodipy-FL-daptomycin, which was a kind gift from Cubist Pharmaceuti-
cals (Lexington, MA). The media for bacterial culture were from Becton
Dickinson Company (Franklin Lakes, NJ).
Bacterial strains, culture conditions, and biofilm model. ATCC
33591 (MRSA) was used as a reference strain. Seven clinical strains iso-
lated from various sites but all belonging to the pandemic clonal com-
plexes CC5 or CC8 were selected from the collection of the Belgian Ref-
erence Centre for S. aureus (Hôpital Erasme, Université Libre de
Bruxelles, Brussels, Belgium). They were characterized as previously de-
scribed (14, 15) with respect to toxin expression and molecular typing
(Table 1).
The biofilms were obtained using as a starting inoculum bacteria
transferred from frozen stocks onto Trypticase soy agar plates and incu-
bated overnight at 37°C, after which 10 colonies were inoculated in
Trypticase soy broth (TSB) supplemented with 2% NaCl and 1% glu-
cose, and the bacterial density was adjusted to an optical density at 620
nm (OD620) of 0.005. For quantitative analysis, 200 l of bacterial
suspension was cultivated in 96-well plates (European catalog no. 734-
2327; VWR [Radnor, PA] tissue culture plates) at 37°C for 24 h so as to
generate a mature biofilm (10). For confocal microscopy studies, the
biofilms were grown on glass coverslips (20 mm in diameter; VWR)
placed in 12-well plates, covered with 4 ml of bacterial suspension, and
incubated at 37°C for 24 h.
Antibiotic susceptibility testing and activity against bacteria grow-
ing in biofilms. Unless stated otherwise, the MICs were determined by
microdilution in cation-adjusted Mueller-Hinton broth (CA-MHB), ac-
cording to the recommendations of the CLSI for delafloxacin and vanco-
mycin, and with addition of CaCl2 (so as to reach a final concentration of
50 mg/liter) for daptomycin (16). Antibiotic activity was determined
against 24-h biofilms, as previously described (10). In brief, the culture
medium was removed and replaced by the same medium (control) or
medium containing antibiotics at increasing concentrations (1- to 256-
fold their MIC in broth). The biofilms were reincubated for 48 h at 37°C
and then treated as previously described (10) for the quantitative deter-
mination of biomass (crystal violet staining) or bacterial viability
(reduction of resazurin in fluorescent resorufin). Crystal violet absor-
bance was measured at 570 nm, and resorufin fluorescence was measured
at an excitation wavelength of 560 nm and an emission wavelength of 590
nm (exc 560/ em 590) using a SPECTRAmax Gemini XS microplate spec-
trofluorometer (Molecular Devices LLC, Sunnyvale, CA).
Assay of polysaccharides. In a first assay, calcofluor white (CFW),
which binds to exopolysaccharides containing beta1-3 and/or beta1-4
linkages (17, 18), was used to compare the exopolysaccharide contents of
the biofilms from different strains. To this effect, 24-h-old biofilms were
washed with 1 ml phosphate-buffered saline (PBS), added with 100 l of
a CFW solution at 0.5 mg/ml, and left for 5 min in the dark at room
temperature. CFW fluorescence was then measured at exc 365/em 440
using a microplate spectrofluorometer. In a second stage, the exopolysac-
charides were purified exactly as previously described (19), after which
their concentrations were determined according to a method described
for quantifying carbohydrates, including polysaccharides (20), using glu-
can as a standard. In brief, 500 l of purified exopolysaccharides was
mixed with 1.5 ml of concentrated sulfuric acid, vortexed for 30 s, and
cooled in ice for 2 min, after which UV light absorption was read at 315
nm. The diameter of exopolysaccharide supramolecular particles was
measured by dynamic light scattering (Zetasizer Nano ZS; Malvern,
France) using 20 l of purified exopolysaccharides dissolved in 980 l of
distilled water (19).
Confocal laser scanning microscopy visualization of biofilms. The
biofilm samples were imaged by confocal laser scanning microscopy in a
Cell Observer SD microscope (Carl Zeiss AG, Oberkochen, Germany)
using spinning disc technology (Yokogawa, Tokyo, Japan) and controlled
by the AxioVision software (AxioVs40 version 4.8.2.0). The biofilms were
stained using either the LIVE/DEAD bacterial viability kit (L-7007), as
described previously (10), or 5-cyano-2,3-ditolyl tetrazolium chloride
(CTC) (RedoxSensor vitality kit; Invitrogen, Carlsbad, CA). CTC is a
colorless, nonfluorescent, and membrane-permeable compound that is
readily reduced via electron transport activity to a fluorescent insoluble
CTC-formazan that accumulates inside bacteria (21). The biofilm-over-
TABLE 1 Description of clinical strains included in the study
Strain
Molecular characterizationf
Clinical origin16Sa nuca mecAb spa typec MLSTd TSST-1e PVLe
2011S027    t002 CC5   Cellulitis and bacteremia
Surv 2003/1083    t002 CC5   Chirurgical wound
Surv 2005/104    t002 CC5   Skin
2009S028    t002 CC5   Nasal carriage
2009S025    t002 CC5   Ear
Surv 2005/179    t008 CC8   Skin
Surv 2003/651    051 CC8   Respiratory infection
a PCR amplification of nuc (S. aureus-specific region of the thermonuclease gene) and of a genus-specific 16S rRNA sequence (14).
b PCR amplification ofmecA (detection of methicillin resistance) (14).
c S. aureus protein A gene (14).
d Multilocus sequence typing allelic profile (clonal complex) (14).
e PCR amplification of TSST-1 and PVL genes encoding the corresponding toxins (15).
f, gene present;, gene absent.
Siala et al.
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grown coverslips were washed with 1 ml PBS buffer, labeled with 0.5 mM
CTC for 30 min, and observed via confocal laser scanning microscopy
(excitation laser line, 488 nm; emission filter, monomeric red fluorescent
protein [mRFP], 598 to 660 nm). The optimal confocal settings (camera
exposure time and confocal scanner unit [CSU] disk speed) were deter-
mined in preliminary experiments. Image stacks of each sample were ac-
quired at a resolution of 700 by 500 pixels and recorded using a z-stack
module for the acquisition of image series from different focus planes and
used to construct three-dimensional images with the AxioVision soft-
ware.
Spatial distribution of biofilm pH microenvironments. Seminaph-
thorhodafluor-4F 5-(and-6) carboxylic acid (C-SNARF-4) is a reliable pH
indicator of the bacterial biofilm microenvironment (22). This dye exists
as amixture of fluorescent forms (monoanionic [naphthol] and dianionic
[naphtholate]) that are predominant at a pHof5 but are nonfluorescent
(neutral and cationic) at lower pH values. The relative concentrations of
the protonated and unprotonated forms, and therefore the local pH, can
be estimated by measuring the 580 nm/640 nm fluorescence ratio using
confocal laser scanningmicroscopy (23). Twenty-four-hour biofilms cul-
tivated on glass coverslips were incubated for 2 h in water, after which
C-SNARF-4 was added at a final concentration of 10M in a volume of 1
ml. The coverslips were then incubated in the dark for 30 min. The solu-
tion was then carefully removed with a pipette. The C-SNARF-4-treated
biofilms were examined by confocal microscopy (excitation at 488 nm
and emission detected in two channels at 580 nm and 640 nm). The
fluorescence intensity was determined by calculating the densitometric
mean for each channel using the outline tool of the AxioVision software.
The ratio of the emission intensity between the two channels was then
calculated, and the microenvironment pH was determined from the
ratio (Fluoem580 sample  Fluoem580 background)/(Fluoem640 sample 
Fluoem640 background) (Fluo, fluorescence), using calibration standards
(solutions of 50 mMHEPES buffer adjusted at pHs ranging from 5.2 to 8,
with a 0.2-pH unit interval) imaged using settings identical to those used
for the biofilm sample (see Fig. S1 in the supplemental material).
Penetration of antibiotics within the biofilms. To study the dela-
floxacin penetrationwithin the biofilms, we took advantage of its intrinsic
fluorescence (exc 395/em 450). Twenty-four-hour biofilm-overgrown
coverslipswere incubated for 1 hwith 50mg/liter delafloxacin dissolved in
distilled water and thereafter stained with the LIVE/DEAD bacterial via-
bility kit, as described above. The biofilms were washed twice with 1 ml
PBS and imaged using confocal microscopy, with the following excita-
tion/emissionwavelengths: 488 nm/500 to 550 nm for Syto 9, 561 nm/570
to 620 nm propidium iodide (for LIVE/DEAD staining), and 400 nm/420
to 450 nm for delafloxacin. To study daptomycin and vancomycin pene-
tration within the biofilms, 24-h biofilms were exposed for 1 h to 20
mg/liter Bodipy-FL-daptomycin or Bodipy-FL-vancomycin and then to
0.5mMCTC for 30min in the dark, and they were washed twice with 1ml
PBS buffer. The confocal images were obtained using an exc of 488 nm
and recording emitted fluorescence at 570 to 620 nm for Bodipy-FL-
labeled antibiotics and 500 to 550 nm for CTC-formazan. The antibiotic
concentrations within the biofilms were then calculated using calibration
curves of the antibiotic solutions examined under the microscope and
using the same settings (concentrations of 5 to 100 mg/liter for delafloxa-
cin and 0.5 to 10 mg/liter for Bodipy-FL-daptomycin and -vancomycin).
Data analyses and statistical analyses. Curve-fitting analyses of the
concentration-effect relationships were made with GraphPad Prism ver-
sion 4.03 (GraphPad Software, San Diego, CA, USA). The data were used
to fit a sigmoid function (Hill equation, variable slope) by nonlinear re-
gression, as previously done with this model [10]) and to calculate the
maximal relative efficacies (Emax) (maximum reduction in biofilm mass
production or in viable bacteria extrapolated for an infinitely large anti-
biotic concentration) and relative potencies (C25, C50, or C75, concentra-
tions allowing 25, 50, or 75% reduction of the parameter investigated,
respectively). Statistical analyses weremadewithGraphPad InStat version
3.06 (GraphPad Software) and correlations with JMP version 10.02 (SAS
Institute, Inc., Cary, NC).
RESULTS
Susceptibility testing. Table 2 shows the activities of the antibiot-
ics against all strains included in this study when tested using
standard susceptibility testing methods (broth microdilution).
TheMICs of daptomycin and vancomycinwere equivalent against
all strains (0.5 and 1 mg/liter, respectively), while those of dela-
floxacin were lower, ranging from 0.004 to 0.125 mg/liter.
Biofilm characterization. Figure 1 (left and middle panels)
compares the viability and the biomass obtained after 24-h culture
of biofilms for the 7 clinical isolates investigated in the present
study in comparison with the S. aureus reference strain ATCC
33591. With respect to viability, three S. aureus clinical strains
(2003/1083, 2009S025, and 2011S027) gave a signal similar to that
of ATCC 33591, while the signal generated by the four other
strains was only 2/3 of this value. With respect to biomass, crystal
violet staining was lower than for the reference strain, with
Surv2003/1083, 2009S025, and Surv2003/651 being the highest
biofilm producers, Surv2005/104 and 2009S28 the lowest produc-
ers, and 2011S027 and Surv2005/179 showing intermediate be-
havior. The content of the biofilms in -polysaccharides was also
estimated using calcofluor white. As illustrated in Fig. 1 (right
panel), biofilm produced by strain Surv2003/651 contained more
polysaccharides than did the biofilms obtained with the other
strains. Yet, when the results were normalized for the amount of
biomass produced, the biofilms obtained from strains Surv2005/
104 and 2009S28 were those containing the highest proportion of
polysaccharides, followed by biofilms from strains 2011S027,
Surv2005/179, and Surv2003/651, and then from strains ATCC
33591, Surv2003/1083, and 2009S025.
Activities of antibiotics against biofilms. Antibiotic activity
was then evaluated against 24-h biofilms incubated for 48 h at a
broad range of antibiotic concentrations in order to obtain full
concentration-effect responses and to calculate the corresponding
parameters of the Hill equation fitted to the data. Typical results
obtainedwith the biofilms formed from2 strains are shown in Fig.
2, with the results for the biofilms obtained from the other strains
presented in Fig. S2 in the supplemental material. The relative
potencies concerning viability are presented in Table 2. They were
presented as C25 values (concentrations reducing the resorufin
fluorescence signal by 25%) because, due to low activity, further
reduction was not obtained for all strains. Against strain
2011S027, all drugs displayed concentration-dependent activity,
with delafloxacin being by far the most potent and the most effi-
cient among the three antibiotics tested, being able to reduce the
biomass by approximately 50% at the lowest concentration tested
(0.1mg/liter) and to almost sterilize the biofilm at a concentration
close to 1 mg/liter. Daptomycin was less potent and less efficient,
while vancomycin was globally poorly active with respect to both
viability and biomass. In sharp contrast, the biofilm produced by
strain Surv2003/651 was totally refractory to all 3 antibiotics, de-
spite the low MICs observed for this strain. Similar to strain
Surv2003/651, strain Surv2005/179was not sensitive to antibiotics
in the biofilms. The biofilms produced by the 4 other clinical iso-
lates showed intermediate behavior, with delafloxacin beingmuch
more effective and potent than the other drugs against strain
2009S025 and with daptomycin being more potent against strains
2009S028 and Surv2005/104. Comparing the relative potencies
Delafloxacin and S. aureus Biofilms
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from a clinical perspective, delafloxacin achieved a 25% reduction
in the resorufin fluorescence signal at a range of clinically achiev-
able concentrations (free human maximum concentration of
drug in serum [Cmax]) against 5 out of the 7 clinical isolates versus
4/7 for daptomycin and 3/7 for vancomycin (Table 2).
We then looked for a possible correlation between the rela-
tive potency of each antibiotic (measured as the C25) and the
characteristics of the biofilms presented in Fig. 1. As illustrated
in Fig. S3 in the supplemental material, there was no significant
correlation between relative potency and biomass (middle pan-
el; P  0.2), but a trend (P, 0.1) to a higher potency for
delafloxacin (i.e., lower C25 values) against biofilms containing
more metabolically active bacteria (higher resorufin fluores-
cence [RF] signal; left panel) or those presenting a smaller pro-
portion of polysaccharides in their matrix (lower CFW-to-
crystal violet [CV] ratio; right panel).
Biofilm microenvironmental pH. An acidic environment is
known to modulate antibiotic intrinsic activity (24) and, more
specifically, to markedly improve that of delafloxacin (11). We
therefore measured the microenvironmental pH (micro-pH) in
the depth of the biofilm using the pH-sensitive probe C-SNARF-4
(22). Table 2 shows the pH valuesmeasured at the top and bottom
of each biofilm, with full data sets illustrated for 3 selected strains
in Fig. 3 (upper panels) and for the other strains in Fig. S4 in the
supplementalmaterial. Biofilms from 6 out of the 7 clinical strains
showed a pH profile similar to that of the reference strain ATCC
33591, with acidic pH recorded at the biofilm surface (5.3 at 0
m to6.0 at 2m) and slightly higher values (0.5 to 1 pH units)
in the deepest plane of the biofilm. Only the biofilm of Surv2005/
179 was almost neutral at the surface (pH 6.8), but the pH deep in
the biofilmwas similar to that observedwith the other strains. The
middle panel of Fig. 3 illustrates for the same strains the influence
of pH on delafloxacin MIC (planktonic bacteria) in a range cov-
ering the pH measured in the biofilms (see Fig. S4 for the other
strains). The MICs were 3 to 9 dilutions lower at the pH of the
biofilm than those at a neutral pH (pH 7.4). In contrast, the van-
comycin and daptomycin MICs were not affected by pH (maxi-
mum 1 dilution change over a pH range from 5.6 to 7.4; data not
shown). The lower panel of Fig. 3 shows the correlation between
the pHmeasured 2 m below the biofilm surface and the relative
TABLE 2 Antibiotic properties and biofilm pHs for the reference strain and the clinical isolates used in the study
Strain Antibiotice MIC (mg/liter)
Concn (mg/liter) causing 25%
reduction in resorufin
fluorescence in biofilmsa
Antibiotic penetration
in biofilm (%)b Biofilm pHc
MRSA ATCC 33591 DFX 0.004 0.002d 60.05 6.12, 5.63
DAP 0.5 1.3 5.99
VAN 1 1.6 0.44
MSSA 2011S027 DFX 0.004 0.2 51.8 5.28, 5.92
DAP 0.5 7.1 9.98
VAN 1 19.5 0.4
MRSA Surv 2003/1083 DFX 0.004 9.2 15.6 6.41, 6.35
DAP 0.5 6.0 4.28
VAN 1 36.0 0.96
MRSA Surv 2005/104 DFX 0.125 13.2 5.72 6.15, 5.46
DAP 0.5 1.2 8.72
VAN 1 15.0 0.24
MRSA 2009S028 DFX 0.016 7.1 16.84 5.94, 5.95
DAP 0.5 0.4 7.32
VAN 1 12.3 0.41
MSSA 2009S025 DFX 0.004 1.5 23.9 5.87, 5.57
DAP 0.5 250 2.64
VAN 1 250 0.26
MRSA Surv 2005/179 DFX 0.016 250 13.02 6.67, 5.71
DAP 0.5 250 0.26
VAN 1 250 0.32
MRSA Surv 2003/651 DFX 0.125 250 0.62 6.19, 5.55
DAP 0.5 250 0.20
VAN 1 250 0.22
a Calculated using the Hill equation of the concentration-response curve (see Fig. 2; see also Fig. S2 in the supplemental material).
b Percentage of the concentration added in the culture medium; see Fig. 4 and also Fig. S5 in the supplemental material.
c Values at 2- and 30-m depths, respectively (Fig. 3; see also Fig. S4 in the supplemental material for values measured at different depths in the biofilm).
d Boldface indicates values that are lower than the free Cmax reached in patients receiving projected doses (DFX Cmax, 10 to 16 mg/liter for intravenous [i.v.] doses of 300 to 450 mg;
free fraction, 84% [28, 29]) or conventional doses (DAP Cmax, 94 mg/liter for i.v. dose of 6 mg/kg of body weight; free fraction, 8.5 % [Cubicin SPC]; VAN Cmax, 63 mg/liter for i.v.
dose of 15 mg/kg; mean free fraction, 45% [vancomycin SPC]).
e DFX, delafloxacin; DAP, daptomycin; VAN, vancomycin.
Siala et al.
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potency of delafloxacin within the biofilms. The correlation was
only partial (strains with similar MICs showing different poten-
cies), suggesting that parameters other than pH influence dela-
floxacin activity within the biofilm.
Antibiotic penetration within the biofilm. The lack of pene-
tration has been reported as a key factor limiting antibiotic activity
against bacteria developing in the depth of biofilms (25–27). We
therefore examined using confocal laser scanning microscopy the
FIG 1 Biofilm characterization. Resorufin fluorescence signal (RF) (left), crystal violet absorbance (CV) (middle), and calcofluor white fluorescence (CFW)
signal (right, squares)measured in 24-h biofilm.The right axis in the right graph showsCFWfluorescence values normalizedwith respect to biomass, as evaluated
by CV absorbance (diamonds). The data are the means	 standard deviations (SD) of 8 wells. Statistical analysis was performed using an analysis of variance
(ANOVA) with Dunnett’s post hoc test; the strains with different letters for each data set denote statistically significant differences among them (*, P
 0.05).
FIG 2 Activities of antibiotics against biofilms. Concentration-response activities of antibiotics against 24-h biofilms of strain 2011S027 (top) or 2003/651 (bottom).
Twenty-four-hour biofilms were incubated with increasing concentrations of antibiotics for 48 h (DFX, delafloxacin; DAP, daptomycin; VAN, vancomycin). The
ordinate shows the change in viability (assessed by resorufinfluorescence; left) or in biomass (assessed by crystal violet absorbance; right) as the percentage of the control
(CT) value (no antibiotic present). All values are themeans	 standard deviations (SD) of 8wells (whennot visible, the SDbars are smaller than the size of the symbols).
Delafloxacin and S. aureus Biofilms
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capacities of the three drugs to diffuse within the biofilm thick-
ness, taking advantage of the fluorescent character of delafloxacin
(blue signal) and using daptomycin or vancomycin coupled to
Bodipy-FL (green signal) as a control. Biofilms were labeled using
LIVE/DEAD staining (green/red staining) for those treated by de-
lafloxacin and CTC (red staining) for those treated by Bodipy-FL-
labeled antibiotics. Table 2 shows the percentage of penetration of
each antibiotic at the surface or in the depth of the biofilm com-
pared to the antibiotic concentration added in the medium bath-
ing the biofilm. Confocal images and fluorescence signal analysis
are shown in Fig. 4 for the three same selected strains and in Fig. S5
in the supplemental material for the other strains. Although vari-
able, the penetration of delafloxacin in the biofilm thickness was
muchbetter than that for the other antibiotics, reaching up to 52%
of the whole structure for the biofilms produced by the clinical
isolates, whereas it did not exceed 10% for Bodipy-FL-daptomy-
cin, and it was
1% for Bodipy-FL-vancomycin. Interestingly, the
penetration of all antibiotics was of the same order of magnitude
in the biofilms produced by the reference strain and by the MSSA
clinical strain 2011S027, against which antibiotics were the most
active. In order to better delineate a potential relationship between
the penetration of the drugs through the biofilm and their activity
on viability within the biofilm, we plotted the relative potency of
each drug (as determined by the concentration needed to reduce
viability within the biofilm by 25% [C25]) versus its relative pen-
etration within the biofilm (using values measured close to the
FIG 3 Micro-pH in biofilms and influence on delafloxacin activity. Top panels, evaluation of micro-pH within biofilms of three selected strains, as
evaluated by confocal microscopy using C-SNARF-4 as a pH-sensitive probe (fluorescence emitted shifting from red to green upon acidification). The
graph below each image shows the corresponding micro-pH in the depth of the biofilm. Middle, influence of pH on the MIC of delafloxacin in MHB
adjusted to different pH values. The gray squares highlight the range of pH measured in the corresponding biofilm. The strain numbers are at the top of
each graph. Bottom, correlation between the relative potency of delafloxacin (C25 [concentration reducing viability by 25%], as determined based on the
concentration-response curves presented in Fig. 2; see also Fig. S2 in the supplemental material) and the MIC at a pH corresponding to the one measured
at 2 m below the surface of the corresponding biofilm.
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surface). StrainMRSA Surv2005/179 was excluded from the anal-
ysis, because the neutral character of its biofilm may constitute a
confounding factor. As shown in Fig. 5, there was a statistically
significant correlation between the relative potency and relative
penetration within the biofilm for delafloxacin and daptomycin,
while vancomycin relative potency was always low, due to poor
penetration of the drug. Figure 5 also shows that a penetration of
5%was sufficient for delafloxacin or daptomycin to achieve a 25%
reduction in viability within the biofilms at a clinicallymeaningful
range of concentrations (MIC free Cmax range; see footnotes to
Table 2 for values). This effect was achieved for 6/7 of the tested
strains for delafloxacin versus 5/7 for daptomycin.
Influence of polyamines on antibiotic activities against bio-
films.Norspermidine and related polyamines have been shown to
trigger the disassembly of S. aureus biofilms by interacting with
matrix exopolysaccharides (19). Because a large diffusion into the
matrix and a low proportion of polysaccharides in the matrix
seemed to critically determine the activities of the antibiotics in
our model, we explored whether the addition of polyamines
would improve this activity by increasing antibiotic penetration.
We first checked that norspermine and norspermidine had no
detectable activity on the biofilms when used alone and did not
change the MICs of the bacteria when tested in broth (planktonic
forms) (data not shown). We then exposed 24-h biofilms to anti-
biotics in the presence of 200Mnorspermidine or norspermine.
The data are illustrated in Fig. 6 for the biofilms produced by
strain Surv2003/651, which were fully refractory to any of the
antibiotics tested when used alone (Fig. 2). Quite strikingly, nor-
spermine and norspermidine markedly improved the activities of
both delafloxacin and daptomycin, so as to reach a 40% reduction
in both resorufin and crystal violet signals at 20mg/liter (the high-
est concentration tested for delafloxacin). This effect was related
to a marked increase in antibiotic relative penetration within the
biofilm (0 to 50% for delafloxacin and 30% for daptomycin). In
contrast, the polyamines added to vancomycin did not im-
prove its penetration within the biofilm and only modestly
improved its efficacy, with no change in potency for viability
and no detectable effect on biomass. To further document the
effect of norspermidine on biofilms, we compared the concen-
trations and sizes of the exopolysaccharides purified from
Surv2003/651 biofilms that were exposed to 200 M norsper-
midine for 24 h or incubated for the same time under control
conditions. Norspermidine drastically reduced both the con-
centrations and the diameters of exopolysaccharide supramo-
lecular particles (27.9 	 3.0 g/ml and 0.95 	 1.2 nm in nor-
spermidine-exposed samples versus 157.9 	 5.2 g/ml and
280.4 	 4.3 nm under control conditions).
Figure 7 illustrates the influence of polyamines on the relative
potencies of the antibiotics against the 7 clinical isolates by show-
ing the concentration of antibiotic needed to cause a 25, 50, or
75% reduction in resorufin fluorescence within a biofilm under
control conditions or in the presence of polyamines (using theHill
equations describing the concentration-effect relationships, as il-
lustrated in Fig. 6 for strain Surv2003/651). Thus, at a concentra-
tion mimicking the anticipated free Cmax of delafloxacin in pa-
tients (13 mg/liter [28, 29]), delafloxacin in combination with
norspermine caused a 25% reduction in resorufin fluorescence
against all 7 strains, 50% against 6 strains, and 75% against 3
strains. Delafloxacin in combination with norspermidine was
slightly less efficient. Norspermidine, and to a lesser extent nor-
spermine, were also highly synergistic with daptomycin, but for
most of the strains, the concentrations needed to reach a 50 or
75% reduction in fluorescence remained higher than the free hu-
FIG 4 Penetration of antibiotics within biofilms. Confocal images of biofilms incubated for 1 h with 50 mg/liter delafloxacin (top [blue]), 20 mg/liter
Bodipy-FL-daptomycin (middle [green]), or 20 mg/liter Bodipy-FL-vancomycin (bottom [green]) and labeled with LIVE/DEAD stain (top: red, dead; green,
live) or CTC (middle and bottom: red). The graphs below each column compare the relative penetration of the drugs within the depth of the corresponding
biofilm, expressed as the percentage of the added concentration (DFX, delafloxacin; DAP, daptomycin; VAN, vancomycin).
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man Cmax (8 mg/liter [Cubicin SPC]). Both polyamines only
slightly improved vancomycin activity.
DISCUSSION
To the best of our knowledge, this study is one of the first to
examine in a systematic fashion the link between the activities of
antibiotics, their penetration within biofilms, the biofilm micro-
pH, and the biofilm polysaccharide content using a series of clin-
ical S. aureus strains from two major contemporary epidemic
clones. Two critical observations are that (i) antibiotic activity is
lower against biofilms produced by these clinical isolates than
against those produced by the reference strains (10), and (ii) there
is huge variability in the susceptibilities of the biofilms produced
by different isolates to the same antibiotic. These differences
might stem from variations in the chemical composition and in
the biophysical properties of the biofilms.
With respect to matrix composition, S. aureus biofilms con-
sist mainly of polysaccharides (poly-N-acetylglucosamine and
teichoic acid), extracellular matrix proteins, and DNA released
from bacteria (30–33), but the relative amounts of these compo-
nentsmay differ among the biofilms formed fromdifferent strains
due to differences in the expression of the genes regulating biofilm
formation (32, 34). The matrix composition of the biofilms
formed by the strains used in our study is not known, but we
observed major differences in the capacities of the strains to form
biofilms. Yet, differences in biomass did not correlate with differ-
ences in antibiotic activity. Actually, there is even a trend toward a
higher potency for delafloxacin against biofilms with higher bio-
mass or viability. This may be due to the fact that fluoroquinolo-
nes are more reliant on bacterial growth than is daptomycin in
order to exert their bactericidal effect (35). Interestingly, dela-
floxacin potencywas inversely proportional to the biofilm content
in polysaccharides relative to the whole biomass. Although the
exact nature of these polysaccharides needs to be determined, the
data are consistent with the generally accepted concept that ex-
opolysaccharides in the matrix represent an initial barrier that
delays the penetration of antimicrobials (36). Of note also, strains
Surv2005/179 and Surv2003/651,which are the least susceptible to
antibiotics when tested in biofilms, are associated with multilocus
sequence type (MLST) CC8, which is claimed to be a stronger
biofilm producer than CC5 (37). In our hands, CC8 rather ap-
peared as producing a matrix rich in polysaccharides, but the
number of strains belonging to this lineage was too low to draw
meaningful conclusions.
With respect to the biophysical properties of the biofilms, we
explored the potential importance of two of them, namely, (i) the
local pH along the thickness of the biofilm and its variation and
(ii) the ability of the biofilms to let antibiotics diffuse into them.
Acidic pH considerably increases the potency of delafloxacin
when tested against planktonic forms of S. aureus by increasing its
intrabacterial accumulation (11), but it does not substantially af-
fect the potency of vancomycin or daptomycin (38 and this study).
Except for one strain, the biofilms were globally slightly acidic,
reaching a pHvalue atwhich delafloxacinMICs are typically 1/100
of those observed at a neutral pH. This may contribute to its su-
perior relative potency compared to that of daptomycin and van-
comycin. But antibiotic access to its bacterial target is also a clear
prerequisite for activity, and biofilms are known to present a bar-
rier to the free diffusion of antibiotics (25, 26, 39, 40). We found
here that the penetration of Bodipy-FL-vancomycin within the
biofilmwas very limited for all strains, whichmay explain the poor
activity of vancomycin. These observations confirm those of Jef-
ferson et al. (41) but are in contradiction to those of Daddi
Oubekka et al. (42), who showed that Bodipy-FL-vancomycin ap-
preciably diffuses within biofilms. The data from Daddi Oubekka
et al., however, were obtained using another experimental ap-
proach that follows the dynamics of the process (correlative time-
resolved fluorescence microscopy) rather than measuring actual
concentrations. Of note, DaddiOubekka et al. did not observe any
antibacterial activity for vancomycin within the biofilms, and
therefore, they concluded that poor penetration was not a critical
FIG 5 Correlation between activity against biofilm and antibiotic penetration
within biofilms. Correlation between the relative potency of antibiotics (C25
[concentration reducing viability by 25%], as determined based on concentra-
tion-response curves presented in Fig. 2; see also Fig. S2 in the supplemental
material) and the penetration of antibiotics within biofilms for all strains,
except strain 2005/179, for which neutral pH may constitute a confounding
factor. The thin dotted lines correspond to the lower MICs of the drug among
the strains tested, and the thick dotted lines correspond to the free humanCmax
for each antibiotic (as observed upon treatment with a conventional dose
projected from clinical trials for delafloxacin; see footnote a in Table 2 for
values). DFX, delafloxacin; DAP, daptomycin; VAN, vancomycin.
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factor in preventing antibiotics from exerting their action within
biofilms. Our data clearly suggest the opposite. Yet, Daddi
Oubekka et al. also propose that the nature of the biofilm matrix
may critically determine the diffusibility of drugs, which is consis-
tent with our own observations. For Bodipy-FL-daptomycin, we
noticed low penetration rates that are in line with the low diffus-
ibility (28%) observed for this molecule in a biofilm formed by a
reference strain of Staphylococcus epidermidis (43). We cannot,
however, exclude that Bodipy itself modifies the diffusion capac-
ities of the drug. While coupling with Bodipy does not change the
MICof vancomycin, it reduces that of daptomycin by about 2-fold
(41, 44). For delafloxacin, which was followed with fluorescence
microscopy without chemical modification, we observed that its
penetration, although highly variable among the biofilms, was,
generally speaking, higher than that of both daptomycin and van-
comycin and clearly correlatedwith antibiotic activity. This higher
capacity of delafloxacin to diffuse in biofilms compared to that of
daptomycin and vancomycin may be at least partly due to its
smaller overall size (molecular mass, 441 g/mol) (45) than that of
vancomycin (1,449 g/mol) and daptomycin (1,620 g/mol), espe-
cially if one considers that coupling with Bodipy increases their
molecular mass by about 275 g/mol. The better penetration of
delafloxacin may also be favorably influenced by the acidic pH
of the biofilm. Delafloxacin, indeed, is a weak acid, with a pKa of
5.6 (calculated with Reaxys; see also reference 11), and its un-
charged species represent, therefore, about half of its total concen-
tration in the depth of the biofilms formed with strains 2005/179
and 2003/651. Putting these parameters together, Fig. 8 illustrates
FIG6 Influence of polyamines on antibiotic activity against biofilmof strain 2003/651. Left, concentration-response activities of antibiotics against 24-h biofilms
incubated with increasing concentrations of antibiotics for 48 h (DFX, delafloxacin; DAP, daptomycin; VAN, vancomycin) in the absence or presence of 200M
norspermine or norspermidine. The ordinate shows the change in viability (assessed by resorufin fluorescence; left) or in biomass (assessed by crystal violet
absorbance; right) as the percentage of the control value (no antibiotic present). All values are themeans	 standard deviations (SD) of 8 wells (when not visible,
the SD bars are smaller than the size of the symbols). The arrows point to the concentration of antibiotic used in confocal microscopy. Middle, confocal images
of biofilms incubated for 1 h with 50 mg/liter delafloxacin (blue), 20 mg/liter Bodipy-FL-daptomycin (green), or 20 mg/liter Bodipy-FL-vancomycin (green) in
the absence or presence of 200 M norspermine and labeled with LIVE/DEAD staining (top: red, dead; green, live) or CTC (middle and bottom: red). Right,
relative penetration (in mg/liter) of the drugs within the depth of the corresponding biofilms, under control conditions, or in the presence of 200 M
norspermidine. The horizontal dotted line corresponds to the MIC of each antibiotic.
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the respective roles of delafloxacin MIC and penetration in the
biofilm on its activity. Thus, strains can be separated into two
clusters with respect to MICs, but their susceptibility to this anti-
biotic within the biofilm rather depends on the capacity of the
drug to reach the bacteria within the structure, which itself is in-
fluenced by the proportion of polysaccharides present in the ma-
trix. This can be explained by the fact that for those biofilms that
are permeable to delafloxacin, the local concentrations are far
FIG 7 Influence of polycations on the activities of antibiotics against biofilms from clinical stains. The graphs show the concentrations of each antibiotic needed
to reach the reductions in viability indicated on the abscissa under control conditions (left) or in the presence of 200Mnorspermidine (middle) or norspermine
(right), calculated based on the equation of sigmoid concentration-response curves obtained for each strain in experiments similar to the one illustrated in Fig.
6. Top, delafloxacin; middle, daptomycin; bottom, vancomycin. The horizontal dotted lines highlight the free serum Cmax values reached (or projected for
delafloxacin) in the sera of patients receiving conventional doses. The thin line separates values that were higher than the highest concentration tested (and were
set arbitrarily at 250 mg/liter).
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above the MIC, whatever its value. Taken together, these data
highlight a potential advantage of delafloxacin over vancomycin
or even daptomycin in this respect. This advantage is further doc-
umented by the drastic gain in relative potency observed for this
drug, and for daptomycin to a lesser extent, when tested in the
presence of norspermidine and norspermine. We show here that
norspermidine andnorsperminemarkedly improve the diffusibil-
ity of antibiotics, especially those with a lowmolecular weight, like
delafloxacin, and cause a commensurate improvement in activity,
which is consistent with a weakening of the matrix meshwork.
Compounds possessing a common motif consisting of three
methylene groups flanked by two amino groups have been shown
to collapse the exopolysaccharide network in Bacillus subtilis bio-
films by interacting with negative charges and favoring biofilm
disassembly (19). Other authors propose instead that norspermi-
dine, added during culture at the concentration used in our ex-
periments, can inhibit biofilm formation in an exopolysaccha-
ride-independent manner by inhibiting B. subtilis growth (46).
None of these authors examined the effect of norspermidine on
preformed biofilms of S. aureus, but the fact that norspermidine
drastically reduces both the content and size of the polysaccha-
rides in the Surv2003/651 biofilm suggests that the first mecha-
nism took place in ourmodel. Yet, whatever the molecular reason
for this synergy, our observations clearly open perspectives in the
search of drug candidates with similar properties to be used as an
adjuvant in biofilm treatments.
A third critical observationmade in this study is that delafloxa-
cin proved to be at least as potent and effective as daptomycin
against these difficult-to-treat biofilms.
Daptomycin is nowadays considered to be an antibiotic of
choice for the treatment of biofilm-related infections (47–51), and
it showed activity against 5 of the 7 isolates tested in our study, if
one considers clinically achievable concentrations. In the range of
its foreseeable clinically relevant concentrations (28, 29), dela-
floxacin displayed activity against 6 of the 7 clinical isolates. Dela-
floxacin is tremendously more potent than other fluoroquinolo-
nes against S. aureus, with MICs as low as 0.001 mg/liter against
susceptible strains and ranging from 0.015 to 1mg/liter for strains
with high-level resistance to both moxifloxacin and levofloxacin
(MICs up to 8 and 64 mg/liter, respectively) (11, 52, 53). There-
fore, delafloxacin may warrant further evaluation in in vivo bio-
film models with Gram-positive organisms as a potential alterna-
tive to the currently available options. Our data also point to the
interest in developing strategies aimed at restructuring the matrix
to be combined with antibiotics in order to improve antibacterial
activity.
ACKNOWLEDGMENTS
We thank Cubist Pharmaceuticals (Lexington, MA) for the kind gift of
Bodipy-FL-daptomycin.
W.S. is a postdoctoral fellow of the program Prospective Research for
Brussels from Innoviris, Belgium. F.V.B. is Maître de recherches of the
Belgian Fonds de la Recherche Scientifique (FRS-FNRS). This work was
supported by the Fonds de la Recherche Scientifique (grants 3.4.588.10F,
3.4530.12, and T.0134.13), the Interuniversity Attraction Poles Pro-
gramme initiated by the Belgian Science Policy Office (program IAP P7/
28), and a grant-in-aid from Melinta Therapeutics, New Haven, CT.
REFERENCES
1. Römling U, Balsalobre C. 2012. Biofilm infections, their resilience to
therapy and innovative treatment strategies. J. Intern. Med. 272:541–561.
http://dx.doi.org/10.1111/joim.12004.
2. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a
common cause of persistent infections. Science 284:1318–1322. http://dx
.doi.org/10.1126/science.284.5418.1318.
3. Lynch AS, Robertson GT. 2008. Bacterial and fungal biofilm infections.
FIG 8 Correlation between relative potency of delafloxacin, its penetration within biofilms, and the proportion of polysaccharides in biofilms (left) or the MIC
of the antibiotic at the biofilm pH (right). Shown are the data from the 7 clinical isolates and ATCC 33591, with relative potency estimated as the C25
(concentration needed to reduced the viability within the biofilms by 25%), penetration within biofilms determined with confocal microscopy (see Table 2 for
values), and the ratio of calcofluor white fluorescence to crystal violet absorbance shown in Fig. 1 or the MIC at the biofilm pH shown in Fig. 3; see also Fig. S4
in the supplemental material. The shaded areas show the normal contour (left panel) or nonparametric density contours (right panel).
Delafloxacin and S. aureus Biofilms
November 2014 Volume 58 Number 11 aac.asm.org 6395
 o
n
 O
ctober 16, 2014 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Annu. Rev. Med. 59:415–428. http://dx.doi.org/10.1146/annurev.med.59
.110106.132000.
4. Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J.
2012. Activity of linezolid and high-dose daptomycin, alone or in combi-
nation, in an in vitro model of Staphylococcus aureus biofilm. J. Antimi-
crob. Chemother. 67:2682–2685. http://dx.doi.org/10.1093/jac/dks272.
5. Mataraci E, Dosler S. 2012. In vitro activities of antibiotics and antimi-
crobial cationic peptides alone and in combination against methicillin-
resistant Staphylococcus aureus biofilms. Antimicrob. Agents Chemother.
56:6366–6371. http://dx.doi.org/10.1128/AAC.01180-12.
6. Kirby AE, Garner K, Levin BR. 2012. The relative contributions of
physical structure and cell density to the antibiotic susceptibility of bacte-
ria in biofilms. Antimicrob. Agents Chemother. 56:2967–2975. http://dx
.doi.org/10.1128/AAC.06480-11.
7. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of
high-dose daptomycin, vancomycin, and moxifloxacin alone or in com-
bination with clarithromycin or rifampin in a novel in vitro model of
Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 54:4329–
4334. http://dx.doi.org/10.1128/AAC.00455-10.
8. John AK, Schmaler M, Khanna N, Landmann R. 2011. Reversible
daptomycin tolerance of adherent staphylococci in an implant infection
model. Antimicrob. Agents Chemother. 55:3510–3516. http://dx.doi.org
/10.1128/AAC.00172-11.
9. Murillo O, Doménech A, Garcia A, Tubau F, Cabellos C, Gudiol F,
Ariza J. 2006. Efficacy of high doses of levofloxacin in experimental for-
eign-body infection by methicillin-susceptible Staphylococcus aureus. An-
timicrob. Agents Chemother. 50:4011–4017. http://dx.doi.org/10.1128
/AAC.00523-06.
10. Bauer J, Siala W, Tulkens PM, Van Bambeke F. 2013. A combined
pharmacodynamic quantitative and qualitative model reveals the potent
activity of daptomycin and delafloxacin against Staphylococcus aureus bio-
films. Antimicrob. Agents Chemother. 57:2726–2737. http://dx.doi.org
/10.1128/AAC.00181-13.
11. Lemaire S, Tulkens PM, Van Bambeke F. 2011. Contrasting effects of
acidic pHon the extracellular and intracellular activities of the anti-Gram-
positive fluoroquinolones moxifloxacin and delafloxacin against Staphy-
lococcus aureus. Antimicrob. Agents Chemother. 55:649–658. http://dx
.doi.org/10.1128/AAC.01201-10.
12. Ohshita Y, Yazaki A. 1997. In vitro studies with WQ-3034, a newly syn-
thesized acidic fluoroquinolone, abstr. F-164. Abstr. 37th Intersci. Conf.
Antimicrob. Agents Chemother., Toronto, Canada. American Society for
Microbiology, Washington, DC.
13. Que YA, Moreillon P. 2014. Staphylococcus aureus (including staphylo-
coccal toxic shock), p 195. InMandell GL, Bennett JE, Dolin R (ed), Man-
dell, Douglas, and Bennett’s principles and practice of infectious diseases.
Elsevier Churchill Livingstone, Philadelphia, PA.
14. Denis O, Deplano A, Nonhoff C, De Ryck R, de Mendonça R, Rottiers
S, Vanhoof R, Struelens MJ. 2004. National surveillance of methicillin-
resistant Staphylococcus aureus in Belgian hospitals indicates rapid diver-
sification of epidemic clones. Antimicrob. Agents Chemother. 48:3625–
3629http://dx.doi.org/10.1128/AAC.48.9.3625-3629.2004.
15. Denis O, Deplano A, De Beenhouwer H, Hallin M, Huysmans G,
Garrino MG, Glupczynski Y, Malaviolle X, Vergison A, Struelens MJ.
2005. Polyclonal emergence and importation of community-acquired
methicillin-resistant Staphylococcus aureus strains harbouring Panton-
Valentine leucocidin genes in Belgium. J. Antimicrob. Chemother. 56:
1103–1106. http://dx.doi.org/10.1093/jac/dki379.
16. Clinical and Laboratory Standards Institute. 2013. Performance stan-
dards for antimicrobial susceptibility testing. 23th informational supple-
ment. CLSI MS100-S23. Clinical and Laboratory Standards Institute,
Wayne, PA.
17. Ramaswamy S, Dworkin M, Downard J. 1997. Identification and char-
acterization of Myxococcus xanthus mutants deficient in calcofluor white
binding. J. Bacteriol. 179:2863–2871.
18. McLennan MK, Ringoir DD, Frirdich E, Svensson SL, Wells DH, Jarrell
H, Szymanski CM, Gaynor EC. 2008. Campylobacter jejuni biofilms
up-regulated in the absence of the stringent response utilize a calcofluor
white-reactive polysaccharide. J. Bacteriol. 190:1097–1107. http://dx.doi
.org/10.1128/JB.00516-07.
19. Kolodkin-Gal I, Cao S, Chai L, Böttcher T, Kolter R, Clardy J, Losick R.
2012. A self-produced trigger for biofilm disassembly that targets exopo-
lysaccharide. Cell 149:684–692. http://dx.doi.org/10.1016/j.cell.2012.02
.055.
20. Albalasmeh AA, Berhe AA, Ghezzehei TA. 2013. A newmethod for rapid
determination of carbohydrate and total carbon concentrations using UV
spectrophotometry. Carbohydr. Polym. 97:253–261. http://dx.doi.org/10
.1016/j.carbpol.2013.04.072.
21. Kim J, Pitts B, Stewart PS, Camper A, Yoon J. 2008. Comparison of the
antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
Antimicrob. Agents Chemother. 52:1446–1453. http://dx.doi.org/10
.1128/AAC.00054-07.
22. Hunter RC, Beveridge TJ. 2005. Application of a pH-sensitive fluoro-
probe (C-SNARF-4) for pH microenvironment analysis in Pseudomonas
aeruginosa biofilms. Appl. Environ. Microbiol. 71:2501–2510. http://dx
.doi.org/10.1128/AEM.71.5.2501-2510.2005.
23. Muller-Borer BJ, Yang H, Marzouk SA, Lemasters JJ, Cascio WE. 1998.
pHi and pHo at different depths in perfused myocardium measured by
confocal fluorescence microscopy. Am. J. Physiol. 275:H1937–H1947.
24. Baudoux P, Bles N, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van
Bambeke F. 2007. Combined effect of pH and concentration on the ac-
tivities of gentamicin and oxacillin against Staphylococcus aureus in phar-
macodynamic models of extracellular and intracellular infections. J. An-
timicrob. Chemother. 59:246–253. http://dx.doi.org/10.1093/jac/dkl489.
25. Pibalpakdee P, Wongratanacheewin S, Taweechaisupapong S, Niumsup
PR. 2012. Diffusion and activity of antibiotics against Burkholderia pseu-
domallei biofilms. Int. J. Antimicrob. Agents 39:356–359. http://dx.doi
.org/10.1016/j.ijantimicag.2011.12.010.
26. Singh R, Ray P, Das A, Sharma M. 2010. Penetration of antibiotics
through Staphylococcus aureus and Staphylococcus epidermidis biofilms.
J. Antimicrob. Chemother. 65:1955–1958. http://dx.doi.org/10.1093/jac
/dkq257.
27. Anderl JN, Franklin MJ, Stewart PS. 2000. Role of antibiotic penetration
limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and
ciprofloxacin. Antimicrob. Agents Chemother. 44:1818–1824. http://dx
.doi.org/10.1128/AAC.44.7.1818-1824.2000.
28. Lawrence L, Benedict M, Hart J, Hawkins A, Danping L, Medlock M,
Hopkins S, Burak E. 2011. Pharmacokinetics (PK) and safety of single doses
of delafloxacin administered intravenously in healthy human subjects, poster
A2-045a. 51th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
American Society forMicrobiology,Washington, DC.
29. Rubino CM, Bhavnani SM, Burak E, Ambrose PG. 2010. Pharmacoki-
netic-pharmacodynamic target attainment analyses supporting delafloxa-
cin phase 3 dose regimen decisions, poster A1-681. Abstr. 50th Intersci.
Conf. Antimicrob. Agents Chemother., Boston,MA.American Society for
Microbiology, Washington, DC.
30. Gil C, Solano C, Burgui S, Latasa C, García B, Toledo-Arana A, Lasa I,
Valle J. 2014. Biofilm matrix exoproteins induce a protective immune
response against Staphylococcus aureus biofilm infection. Infect. Immun.
82:1017–1029. http://dx.doi.org/10.1128/IAI.01419-13.
31. Kogan G, Sadovskaya I, Chaignon P, Chokr A, Jabbouri S. 2006.
Biofilms of clinical strains of Staphylococcus that do not contain polysac-
charide intercellular adhesin. FEMSMicrobiol. Lett. 255:11–16. http://dx
.doi.org/10.1111/j.1574-6968.2005.00043.x.
32. Sadovskaya I, Chaignon P, Kogan G, Chokr A, Vinogradov E, Jabbouri
S. 2006. Carbohydrate-containing components of biofilms produced in
vitro by some staphylococcal strains related to orthopaedic prosthesis in-
fections. FEMS Immunol. Med. Microbiol. 47:75–82. http://dx.doi.org
/10.1111/j.1574-695X.2006.00068.x.
33. Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L,
Tsang LH, Smeltzer MS, Horswill AR, Bayles KW. 2009. Modulation of
eDNA release and degradation affects Staphylococcus aureus biofilm
maturation. PLoS One 4:e5822. http://dx.doi.org/10.1371/journal.pone
.0005822.
34. Atshan SS, Shamsudin MN, Sekawi Z, Lung LTT, Hamat RA, Karu-
nanidhi A, Ali AM, Ghaznavi-Rad E, Ghasemzadeh-Moghaddam H,
Seng JSC, Nathan JJ, Pei CP. 2012. Prevalence of adhesion and regulation
of biofilm-related genes in different clones of Staphylococcus aureus.
J. Biomed. Biotechnol. 2012:976972. http://dx.doi.org/10.1155/2012
/976972.
35. Mascio CT, Alder JD, Silverman JA. 2007. Bactericidal action of dapto-
mycin against stationary-phase and nondividing Staphylococcus aureus
cells. Antimicrob. Agents Chemother. 51:4255–4260. http://dx.doi.org/10
.1128/AAC.00824-07.
36. Mah TF, O’Toole GA. 2001. Mechanisms of biofilm resistance to antimi-
crobial agents. Trends Microbiol. 9:34–39. http://dx.doi.org/10.1016
/S0966-842X(00)01913-2.
Siala et al.
6396 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 16, 2014 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
37. Croes S, Deurenberg RH, Boumans MLL, Beisser PS, Neef C, Stobber-
ingh EE. 2009. Staphylococcus aureus biofilm formation at the physiologic
glucose concentration depends on the S. aureus lineage. BMC Microbiol.
9:229. http://dx.doi.org/10.1186/1471-2180-9-229.
38. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van
Bambeke F. 2006. Pharmacodynamic evaluation of the intracellular ac-
tivities of antibiotics against Staphylococcus aureus in a model of THP-1
macrophages. Antimicrob. Agents Chemother. 50:841–851. http://dx.doi
.org/10.1128/AAC.50.3.841-851.2006.
39. Rodríguez-Martínez JM, Ballesta S, Pascual A. 2007. Activity and
penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid
and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa bio-
films. Int. J. Antimicrob. Agents 30:366–368. http://dx.doi.org/10.1016/j
.ijantimicag.2007.05.005.
40. Stewart PS. 2002. Mechanisms of antibiotic resistance in bacterial bio-
films. Int. J. Med. Microbiol. 292:107–113. http://dx.doi.org/10.1078
/1438-4221-00196.
41. Jefferson KK, Goldmann DA, Pier GB. 2005. Use of confocal microscopy
to analyze the rate of vancomycin penetration through Staphylococcus au-
reus biofilms. Antimicrob. Agents Chemother. 49:2467–2473. http://dx
.doi.org/10.1128/AAC.49.6.2467-2473.2005.
42. Daddi Oubekka S, Briandet R, Fontaine-Aupart MP, Steenkeste K.
2012. Correlative time-resolved fluorescence microscopy to assess antibi-
otic diffusion-reaction in biofilms. Antimicrob. Agents Chemother. 56:
3349–3358. http://dx.doi.org/10.1128/AAC.00216-12.
43. Stewart PS, Davison WM, Steenbergen JN. 2009. Daptomycin rapidly
penetrates a Staphylococcus epidermidis biofilm. Antimicrob. Agents Che-
mother. 53:3505–3507. http://dx.doi.org/10.1128/AAC.01728-08.
44. Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated
reorganization of membrane architecture causes mislocalization of essen-
tial cell division proteins. J. Bacteriol. 194:4494–4504. http://dx.doi.org
/10.1128/JB.00011-12.
45. Stewart PS. 2003. Diffusion in biofilms. J. Bacteriol. 185:1485–1491. http:
//dx.doi.org/10.1128/JB.185.5.1485-1491.2003.
46. Hobley L, Kim SH, Maezato Y, Wyllie S, Fairlamb AH, Stanley-Wall
NR, Michael AJ. 2014. Norspermidine is not a self-produced trigger for
biofilm disassembly. Cell 156:844–854. http://dx.doi.org/10.1016/j.cell
.2014.01.012.
47. Meije Y, Almirante B, Del Pozo JL, Martín MT, Fernández-Hidalgo N,
Shan A, Basas J, Pahissa A, Gavaldà J. 2014. Daptomycin is effective as
antibiotic-lock therapy in a model of Staphylococcus aureus catheter-
related infection. J. Infect. http://dx.doi.org/10.1016/j.jinf.2014.01.001.
48. Seaton RA, Malizos KN, Viale P, Gargalianos-Kakolyris P, Santantonio
T, Petrelli E, Pathan R, Heep M, Chaves RL. 2013. Daptomycin use in
patients with osteomyelitis: a preliminary report from the EU-CORESM
database. J. Antimicrob. Chemother. 68:1642–1649. http://dx.doi.org/10
.1093/jac/dkt067.
49. Domínguez-Herrera J, Docobo-Pérez F, López-Rojas R, Pichardo C,
Ruiz-Valderas R, Lepe JA, Pachón J. 2012. Efficacy of daptomycin versus
vancomycin in an experimental model of foreign-body and systemic in-
fection caused by biofilmproducers andmethicillin-resistant Staphylococ-
cus epidermidis. Antimicrob. Agents Chemother. 56:613–617. http://dx
.doi.org/10.1128/AAC.05606-11.
50. Van Praagh AD, Li T, Zhang S, Arya A, Chen L, Zhang XX,
Bertolami S, Mortin LI. 2011. Daptomycin antibiotic lock therapy in
a rat model of staphylococcal central venous catheter biofilm infec-
tions. Antimicrob. Agents Chemother. 55:4081–4089. http://dx.doi
.org/10.1128/AAC.00147-11.
51. LaPlante KL, Woodmansee S. 2009. Activities of daptomycin and van-
comycin alone and in combination with rifampin and gentamicin against
biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an
experimental model of endocarditis. Antimicrob. Agents Chemother. 53:
3880–3886. http://dx.doi.org/10.1128/AAC.00134-09.
52. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, Devito JA. 2012.
Activity of delafloxacin against methicillin-resistant Staphylococcus au-
reus: resistance selection and characterization. J. Antimicrob. Chemother.
67:2814–2820. http://dx.doi.org/10.1093/jac/dks307.
53. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD. 2004.
In vitro and bactericidal activities of ABT-492, a novel fluoroquin-
olone, against Gram-positive and Gram-negative organisms. Antimi-
crob. Agents Chemother. 48:2771–2777. http://dx.doi.org/10.1128
/AAC.48.7.2771-2777.2004.
Delafloxacin and S. aureus Biofilms
November 2014 Volume 58 Number 11 aac.asm.org 6397
 o
n
 O
ctober 16, 2014 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Siala et al. - Delafloxacin and S. aureus biofilms - Page 1 of 5 
Siala-biofilm-clinical-strains-21-05-2014-SP.doc - 28/05/2014  - Last saved by Françoise Van Bambeke 
 
Supplemental material  
Antibiotic activity against biofilms from Staphylococcus aureus clinical isolates: 
factors determining the activity of the investigational fluoroquinolone delafloxacin 
in comparison with daptomycin and vancomycin. 
Wafi Siala, Marie-Paule Mingeot-Leclercq, Paul M. Tulkens, Marie Hallin, Olivier Denis, 
and Françoise Van Bambeke. 
 
 
 
Figure S1 
 
Calibration curve used for pH determination within biofilm.  C-SNARF-4 solutions at different pH 
were examined in confocal scanning laser microscopy and fluorescence was recoded at 580 and 
640 nm upon excitation at 488 nm. The built equation [calculated from the equation of the 
sigmoidal regression : Fluorescence ratio =BOTTOM + (TOP-BOTTOM)/(1+10^((LogEC50-
pH)*HILLSLOPE))]  was used to estimate pH within biofilms stained with C-SNARF-4.  
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Figure S2 
 
Concentration-response activity of 
antibiotics against 24 h biofilms of 
clinical isolates and of ATCC33591 
(reference strain).  24h biofilms 
were incubated with increasing 
concentrations of antibiotics for 48 
h (DFX: delafloxacin, DAP: 
daptomycin; VAN: vancomycin).  
The ordinate shows the change in 
viability (assessed by the resorufin 
fluorescence; left) or in biomass 
(assessed by crystal violet 
absorbance; right) in percentage of 
the control value (no antibiotic 
present).  All values are means ± 
standard deviations (SD) of 8 wells 
(when not visible, the SD bars are 
smaller than the size of the 
symbols).   
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Figure S3 
Correlation between capacity of forming biofilms in control conditions (left: viability, as 
assessed by resorufin [RF] fluorescence; middle, biomass, as assessed by crystal violet [CV] 
absorbance) or the relative proportion of polysaccharide in each biofilm matrix (as assessed 
by the calcofluor white [CFW] fluorescence-to-crystal violet [CV] absorbance ratio) and the 
relative potency of antibiotics  (C25 [concentration reducing viability of 25%] as determined 
based on concentration-response curves presented in Figures 2 and S2). DFX: delafloxacin, 
DAP: daptomycin; VAN: vancomycin).  Data from MRSA ATCC33591 and all clinical isolates. 
Signification probability values from the analysis of variance. 
 
 
 
 
 
Siala et al. - Delafloxacin and S. aureus biofilms - Page 4 of 5 
Siala-biofilm-clinical-strains-21-05-2014-SP.doc - 28/05/2014  - Last saved by Françoise Van Bambeke 
 
 
Figure S4 
  
Top panel: Evaluation of micropH within biofilm of clincial isolates as evaluated in confocal microscopy using C-SNARF-4 as a pH sensitive 
probe (fluorescence emitted shifting from red to green upon acidification).  The graph below each image shows the corresponding micropH in 
the deepness of the biofilm. 
Middle panel: influence of pH on the MIC of delafloxacin in MHB adjusted to different pH values.  Gray squares highlight the range of pH 
measured in the corresponding biofilm. 
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Figure S5 :  
 
Confocal images of biofilm incubated during 1 h with 50 mg/L delafloxacin (top [blue]), 20 mg/L Bodipy-FL daptomycin (middle [green]) or 20 
mg/L Bodipy-FL vancomycin (bottom [green]) and labeled with live/dead staining (top [red: dead; green: live]) or CTC (bottom [red]).  
The graphs below each column compares the relative penetration of the drugs within the depth of the corresponding biofilms, expressed in 
percentage of the added concentration (DFX: delafloxacin, DAP: daptomycin; VAN: vancomycin).  
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Confocal images of biofilm incubated during 1 h with 50 mg/L delafloxacin (top [blue]), 20 mg/L Bodipy-FL daptomycin (middle [green]) or 20 
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